BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Thermo Fisher Scientific invests Rs 160 Cr+ to expand Bengaluru R&D facility

27 October 2025 | News

The centre will create 100+ jobs in Karnataka in the coming years



Thermo Fisher Scientific's expanded Research and Development (R&D) Centre of Excellence was officially inaugurated in Bengaluru by Sanjeev Kumar Gupta, CEO, Karnataka Digital Economy Mission (KDEM).

This facility is committed to pioneering advances in antibody design, development, and manufacturing. It represents a significant milestone in the company's efforts to accelerate innovation and scientific collaboration from India.

Thermo Fisher has invested over Rs 160 crore in this expansion, reinforcing its long-term commitment to India's research ecosystem. The expanded 37,000 sq. ft. facility incorporates advanced automation and analytical platforms to support immunoassays, protein analysis, and cell-based studies. In the coming years, the expansion will create 100+ jobs, strengthening local talent development and contributing to Karnataka's thriving life sciences ecosystem.

Speaking about the occasion, Priyank Kharge, Minister for Electronics, IT & Biotechnology and Rural Development & Panchayat Raj, Government of Karnataka, said, "Karnataka has long positioned itself as a vibrant hub for biotechnology and life sciences. The expansion of Thermo Fisher's facility is a testament to the state's continued emphasis of this objective. Through our Karnataka Biotechnology Mission and aligned state policies, we are enabling innovation, nurturing talent, and facilitating collaboration between government, academia and industry. This facility strengthens the state's capability to contribute meaningfully to India's broader biotechnology vision."

With this expansion, Thermo Fisher's Bengaluru Centre of Excellence continues to serve as a cornerstone of its global R&D network. Over the past 18 years, the facility has developed more than 2,000 high-quality recombinant antibodies that have contributed to advancements in infectious diseases, antiviral studies, and cancer biology. Its antibody validation programme has tested over 25,000 antibodies, while manufacturing capabilities have produced more than 2,000 primary and secondary antibodies, ensuring quality and reproducibility for researchers worldwide.

Bengaluru is Thermo Fisher's strategic hub in India, with more than 1,400 professionals working across R&D, software, and scientific product teams.

Image caption- From L to R: Gianluca Pettiti, Executive Vice President and Sector President, Life Sciences, Diagnostics and Applied Sector, Thermo Fisher Scientific and Sanjeev Kumar Gupta, CEO, Karnataka Digital Economy Mission inaugurating the company's expanded Research and Development (R&D) Centre of Excellence in Bengaluru